Patients with primary brain tumors.
The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs). Initial results of the trial demonstrated a progression-free survival benefit with adjuvant PCV, but no overall survival benefit in the intention-to-treat analysis. Because patients with LGGs have favorable prognostic indicators, the five-year overall survival rates range from 60%-70%. The effect of cancer treatment on neurocognitive function is a topic of increasing interest to healthcare providers and patients. The negative effect is commonly called "chemobrain" and refers to diminished concentration and compromised short-term memory following treatment. Chemobrain has been studied in other populations of patients with cancer (e.g., breast cancer) with associated statistically significant chemotherapy-associated compromised cognitive function when chemotherapy was added to RT.
['Behrend|Susan Weiss|SW|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D001932:Brain Neoplasms D017024:Chemotherapy, Adjuvant D003072:Cognition Disorders D005260:Female D005910:Glioma D006801:Humans D008130:Lomustine D008297:Male D008875:Middle Aged D011344:Procarbazine D011446:Prospective Studies D014750:Vincristine D055815:Young Adult
primary brain tumors cognitive function low-grade glioma uncertainty